So these patients are not the same patients from the cohort 3 dose escalation 12GBq phase? They are fresh set of patients who will be given from 2-4 doses depending on SRC approval to amend the trial design.
I am guessing that the results so far are encouraging to clinicians and patients to join the trials where other therapies have failed especially with literally zero downside or AEs?
Ann: First participant treated in the last dose escalation cohort, page-3
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.22 |
Change
0.000(0.00%) |
Mkt cap ! $1.625B | |||
| Open | High | Low | Value | Volume |
| $5.23 | $5.29 | $5.11 | $3.861M | 741.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1159 | $5.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.22 | 6688 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$5.22 |
Change
0.000 ( 0.26 %) |
||||
| Open | High | Low | Volume | ||
| $5.26 | $5.28 | $5.11 | 196370 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| CU6 (ASX) Chart |
